6. Analyse
6.8 Nedleggelse av Moss lufthavn Rygge (MLR)
As cepas de P. aeruginosa avaliadas nesse trabalho mostraram que esse microrganismo é mais frequentemente encontrado em isolados de secreção e de urina. O padrão fenotípico de resistência das amostras analisadas mostrou altas taxas de resistência, principalmente a fluoroquinolonas, seguida por beta-lactâmicos associados aos inibidores de -lactamases, cefalosporinas e carbapenêmicos. Também foi observada uma alta frequência na detecção de enzimas do tipo AmpC e metallo- -lactamases, resultado esse que chama a atenção, visto que esses mecanismos de resistência inviabilizam diversas terapias antimicrobianos e dificultam o tratamento de infecções causadas por esse patógeno.
A partir dos dados obtidos conclui-se que, muito embora a compreensão sobre P. aeruginosa ao longo do tempo tenha avançado, esta bactéria continua a ser um flagelo em hospitais, causando infecções virulentas e devido a sua capacidade de desenvolver resistência as mais variadas classes de antimicrobianos, torna-se muito difícil o tratamento de pacientes acometidos.
Os resultados evidenciam a importância da detecção de mecanismos de resistência como a produção de beta-lactamases, assim como o estabelecimento de critérios para utilização de antibióticos a fim de minimizar os riscos de desenvolvimento de resistência.
Trata-se de um estudo pioneiro no Estado do Rio Grande do Norte que de certa forma servirá como base para estudos mais aprofundados no que refere à resistência a antimicrobianos em espécies de P. aeruginosa. A identificação precoce de patógenos e a análise da resistência de microrganismos aos antimicrobianos constituem importante ferramenta para auxiliar os clínicos no tratamento de infecções. Dessa forma, conhecer o perfil de susceptibilidade aos antibióticos de P. aeruginosa pode nortear a escolha de terapia empírica. Além disso, o conhecimento dos mecanismos de resistência deste agente, presentes em cada instituição é de extrema importância para conter a disseminação de microrganismos multirresistentes reduzindo morbi-mortalidade de pacientes internados em nossos hospitais.
ALOUSH V, et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. [S.l.], 50(1):43-8. 2006;
ALOUSH, V. et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother, [S.l.], v. 50, n. 1, p. 43-8, 2006.
ALMEIDA M.G.C., et al. Perfil de sensibilidade a antimicrobianos em Pseudomonas aeruginosa de origem hospitalar e ambulatorial oriundas de laboratórios público e privado, em Belém, estado do Pará. RBAC. 44:44-9; 2012.
AMBLER R.P. The Structure of -Lactamases. Biological Sciences, [S.l.], v. 289, n.1036, p. 321-331, 1980.
AMBLER RP, et al. A standard numbering scheme for the class A beta- lactamases. Biochem J. [S.l.], May 15;276 ( Pt 1):269-70, 1991.
AGÊNCIA NACIONAL DE VIGILÂNCIA SANTITÁRIA. Nota técnica nº 01/2013: medidas de prevenção e controle de infecções por enterobactérias multiresistentes. Brasília, 2013. Disponível em: < http://portal.anvisa.gov.br/wps/wcm/connect/ea4d4c004f4ec3b98925d9d785749 fbd/Microsoft+Word++NOTA+T%C3%89CNICA+ENTEROBACTERIAS+17+0 +2013%281%29.pdf?MOD=AJPERES>. Acesso em: 20 out. 2014.
BABIC, M.; HUJER, A. M.; BONOMO, R. A. What's new in antibiotic resistance? Focus on -lactamases. Drug Resistance Update, [S.l.], v. 9, n. 3, p. 142-56, 2006.
BALASUBRAMANIAN, L. et al. A dynamic and intricate regulatory network determines Pseudomonas aeruginosa virulence. Nucleic Acids Res., [S.l.], 41, pp. 11–20, 2013
BARLOW, M. et al. Revised Ambler classification of -lactamases. The Journal of Antimicrobial Chemotherapy, [S.l.], v. 55, n. 6, p. 1050-1, 2005.
BARTLETT J. G. Pocket Book of Infectious Disease Therapy. Bartlett Price JG, Ed. Baltimore: Williams & Wilkins [S.l.],. p.236. 2004.
Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. [S.l.], 43(Suppl. 2), 49–56 2006.
BOSSO, J. A., MARTHA L. HAINES, AND JUANMANUEL GOMEZ. “Stable Susceptibility to Aminoglycosides in an Age of Low Level, Institutional Use.”Infectious Diseases and Therapy [S.l.], 2.2 209–215. PMC. 2013
BRADFORD, A. P. Extended-Spectrum -lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. Clinical Microbiology Reviews, [S.l.], v. 14, n. 4, p.933- 51, 2001.
BUSH K, JACOBY G, MEDEIROS A. A functional classification scheme for - lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. [S.l.], 39:1211-33 1995.
BUSH K, et al. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother. [S.l.],; 37: 851-8, 1993.
CANTÓN R., et al. European Network on Carbapenemases. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. [S.l.],18(5):413-431, 2012.
CARVALHO, K. R. Detecção de Beta lactamases em Pseudomonas aeruginosa isoladas de pacientes internados em hospitais de São Luis do Maranhão. 2004. 74 f. Dissertação (Mestrado em Vigilância Sanitária) - Instituto Nacional de Controle de Qualidade em Saúde, Fundação Oswaldo Cruz, Rio de Janeiro, 2004.
CASAL M.M., CAUSSE M., RODRÍGUEZ. M., CASAL M. Resistencia antimicro
biana en aislados clínicos de Pseudomonas
aeruginosa Hospital Reina Sofía. Servicio de Microbiología y Parasitologí a, Códo a (España) Rev E Quimioter. [S.l.], 25(1): 37‐41, 2012.
Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. Atlanta, GA: Centers for Disease Control and Prevention; 2013.
forAcinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniaeclinical isolates. J. Antimicrob. Chemother. [S.l.], 69 275–277 10.1093/jac/dkt315, 2013.
CORNAGLIA, G. H. GIAMARELLOU, G.M. ROSSOLIN. Metallo-β- lactamases: a last frontier for β-lactams? Lancet Infect. Dis., [S.l.], 11 pp. 381–393, 2011.
DRAWZ, S. M, BONOMO, R. Three decades of beta-lactamase inhibitors. Clinical Microbiology Review, [S.l.], v. 23, n. 1, p. 160-201, 2010.
DRLICA K., et al. Quinolones: action and resistance updated. Curr. Top. Med. Chem. 9, 981–998, 2009.
DRLICA K., ZHAO X. DNA gyrase, topoisomerase IV, and the 4- quinolones.Microbiol. Mol. Biol. [S.l.], Rev. 61, 377–392, 1997.
Dunne WM, Hardin DJ. Use of Several Inducer and Substrate Antibiotic Combinations in a Disk Approximation Assay Format To Screen for AmpC
Induction in Patient Isolates of Pseudomonas
aeruginosa, Enterobacter spp.,Citrobacter spp., and Serratia spp. Journal of Clinical Microbiology. [S.I.];43(12):5945-5949, 2005.
ERNST RK, MILLER SI. Peptides, pseudomonas aeruginosa, polysaccharides and lipopolysaccharides—players in the predicament of cystic fibrosis patients: response. Trends Microbiol. [S.l.], 8:250–251, 2000.
EUZÉBY, J.P. LPSN. List of prokaryotic names with standing in nomenclature. Disponível em: <http://www.bacterio.cict.fr/>. Acesso em: 10 out. 2014.
FERNANDEZ L., et al. Characterization of the polymyxin B resistome of Pseudomonas aeruginosa.Antimicrob. Agents Chemother. [S.l.], 57 110– 119 10.1128/AAC.01583-12, 2013.
FERNANDEZ L, HANCOCK RE. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev. [S.l.], 25(4):661-81. 2012.
resistência a múltiplos fármacos e resistência cruzada entre antimicrobianos no Recife/PE. Rev Bras Ter Intensiva [S.l.], 19: 421-427, 2007.
FLUIT, A.C.; VERHOEF, J.; SCHMITZ, F.J.; EUROPEAN SENTRY PARTICIPANTS. Frequency of isolation and antimicrobial resistance of Gram- negative and Gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance ProGram 1997-1998. Eur. J. Clin. Microbiol. Infect. Dis., [S.l.], v. 20, n. 9, p. 617-25, Sep, 2001.
FRANCO M.R, et al. Metallo-beta-lactamases among imipenem- resistant Pseudomonas aeruginosa in a Brazilian university hospital. Clinics (Sao Paulo) 65:825–9, 2010.
FREITAS A.L., Barth A.L. Typing of Pseudomonas aeruginosa from hospitalized patients: a comparison of susceptibility and biochemical profiles with genotype. Braz J Med Biol [S.l.], Res 37:77-82, 2004.
GALES AC, et al. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance ProGram (Latin America, 2008-2010). Diagn Microbiol Infect Dis. [S.l.], 73(4):354-60, 2012.
GALES AC, et al. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta- lactamase. J Antimicrob Chemother. [S.l.], 52:699–702, 2003.
GALES AC, SADER HS, JONES RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance ProGram (1997-2000). Diagn Microbiol Infect Dis [S.l.], 44:301-11, 2002.
GALES AC, SADER HS, JONES RN; SENTRY Participants Group (Latin America). Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance proGram (1997-2000). Diagn Microbiol Infect Dis [S.l.], 44:289-99, 2002.
GAYNES R, EDWARDS JR. Overview of nosocomial infections caused by Gram-negative bacilli.Clin. Infect. Dis. 41(6):848–854 •• Data from National Nosocomial Infections Surveillance System [S.l.], (1986–2003) showing
organisms, 2005.
GELLATLY S. L., HANCOCK R. E. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog. Dis. [S.l.], 67 159–173 10.1111/2049-632X.12033, 2013.
GNIADKOWSKI, M. Evolution of extended-spectrum -lactamases by mutation. Clinical Microbiology and Infection, [S.l.], v. 14 Suppl 1, n., p. 11-32, 2008. GUTIERREZ O, et al. Molecular epidemiology and mechanisms of carbapenem resistance inPseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob. Agents Chemother. [S.l.], 51, 4329– 433510.1128/AAC.00810-07, 2007.
HALL, B. G.; BARLOW, M. Evolution of the serine -lactamases: past, present and future. Drug Resistance Update, [S.l.], v. 7, p. 111-123, 2004.
HARTZELL JD, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. [S.l.];48(12):1724–1728, 2009.
HEAD, N. E. ; Y.U. H. Cross-sectional analysis of clinical and environmental isolates of Pseudomonas aeruginosa: biofilm formation, virulence, and genome diversity. Infect. Immun. [S.l.], 72: 133-144, 2004.
HENRICHFREISE B., et al. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob. Agents Chemother. [S.l.], 51, 4062– 407010.1128/AAC.00148-07, 2007.
HENRY, D.A.; SPEERT, D.P. Pseudomonas In: MURRAY, P.R.; BARON, E.J.; JORGENSEN, J.H.; LANDRY, M.L., PFALLER, M.A. Manual of Clinical Microbiology, 10th ed. American Society for Microbiology: Washington, v. 1, Cap. 40, p. 734, 2011.
HIDRON A.I., et al. RIDKIN SK, National Healthcare Safety Network Team, Participating National Healthcare Safety Network Facilities (2008) NHSN annual update: antimicrobial-resistant pathogens associated with healthcare- associated infections: annual summary of data reported to the NHSN at the
Epidemiol 29: 996–1011, [S.l.], 2008.
HILL, E.B.; HENRY, D.A.; SPEERT, D.P. Pseudomonas In: MURRAY, P.R.; BARON, E.J.; JORGENSEN, J.H.; LANDRY, M.L., PFALLER, M.A. Manual of Clinical Microbiology, 9th ed. American Society for Microbiology: Washington, v. 1, Cap. 48, p. 734, 2007
HOBAN DJ, et al. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis [S.l.], 45:279-85, 2003.
HODLE A.E. RICHTER KP. THOMPSON RM. Infection control practices in U.S. burn units. J Burn Care Res. [S.l.], 27:142–151, 2006.
HONG M., HSU D., BOUNTHAVONG M. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and -lactamase-inhibitor combination. Infect. Drug Resist., 6 [S.l.], pp. 215–223, 2013
HOOPER, D. C. Mechanisms of fluoroquinolone resistance. Drug Resist. Updat. [S.l.], 2:38-55, 1999.
HONG M., HSU D., BOUNTHAVONG M. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and -lactamase-inhibitor combination. Infect. Drug Resist., [S.I.] 6, pp. 215–223, 2013.
HORIANOPOULOU M, et al. Frequency and predictors of colonization of the respiratory tract by VIM-2-producingPseudomonas aeruginosa in patients of a newly established intensive care unit. J Med Microbiol. [S.l.], 55:1435–9, 2006.
HU H.C., et al. “Comparative Genome Analysis of Ciprofloxacin-Resistant Pseudomonas aeruginosa Reveals Genes Within Newly Identified High Variability Regions Associated With Drug Resistance Development.” Microbial Drug Resistance [S.l.], 19(6): 428-436, 2013.
HUSSAIN, M. et al. Cloning and sequencing of the metallothioprotein - lactamase II gene of Bacillus cereus 569/H in Escherichia coli. J. Bacteriol. [S.l.],, v.164, n.1, p.223-229, 1985.
in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clin. Microbiol. Infect. [S.l.], 15, 60–66, 2009.
JACK D.L, YANG N.M, SAIER M.H., J.R. The drug/metabolite transporter superfamily. Eur J Biochem. [S.l.], 268(13):3620–39, 2001.
JACOBY, G. A.; MILLS, D. M.; CHOW, N. Role of -lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, [S.l.], v. 48, n. 8, p. 3203-6, 2004. JACOBY G. A, MUNOZ-PRICE LS. The new beta-lactamases. N Engl J Med. [S.l.], 352:380–91, 2005.
JACOBY G. A. (Mechanisms of resistance to quinolones. Clin. Infect. Dis. [S.l.], 41(Suppl. 2), S120–S126, 2005.
JACOBY G.A, (2009) AmpC beta-lactamases. Clin Microbiol Rev [S.l.], 22:161-82, 2009.
JÁCOME P.R.L.A., et al. Phenotypic and molecular characterization of antimicrobial resistance and virulence factors in Pseudomonas aeruginosa clinical isolates from Recife, State of Pernambuco, Brazil. Rev Soc Bras Med Tropical [S.l.], 45:707-712, 2012.
JIMENEZ P.N., et al.The multiple signaling systems regulating virulence in Pseudomonas aeruginosa Microbiol. Mol. Biol. Rev., 76 [S.l.], pp. 46–65, 2012
JUAN C, et al. Molecular mechanisms of -lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother. [S.l.]; 49: 4733-8, 2005.
KIRBY, W. M. M. Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science, [S.l.], 99:452-453, 1944.
KISKA O.L. e GILLIGAN P.H. Pseudomonas. In: Murray PR, Baron FJ, Pfaller MA, Tenover FC, Yolken RH. Manual of clinical microbiology. 7th ed. Americait Society for Microbiology. Washington. [S.l.]; 5:516-526, 2003.
KLIEBE C., et al. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrobial Agents and Chemotherapy, [S.l.], v. 28, p. 302–307, 1985.
KNOTHE, H., et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection, [S.l.], v. 11, n. 6, p. 315-7, 1983
KONG F., et al. Pseudomonas aeruginosa pyocyanin inactivates lung epithelial vacuolar ATPase-dependent cystic fibrosis transmembrane conductance regulator expression and localization. Cell Microbiol [S.l.], 8: 1121-1133, 2006.
KONEMAN E W, et al. Fifth edition. In: Color atlas and textbook of diagnostic microbiology. Lippincott. Philadelphia, 1997.
KUMAR V, et al.. Burden of different beta-lactamase classes among clinical isolates of AmpC-producing Pseudomonas aeruginosa in burn patients: A prospective study. Indian J Crit Care Med [S.l.]; 16:136-40, 2012.
KURODA T, TSUCHIYA T. Multidrug efflux transporters in the MATE family. Biochim Biophys Acta. [S.l.]; 1794(5):763–8, 2009.
KUWABARA, S.; ABRAHAM, E.P. Some properties of two extracellular - lactamases from Bacillus cereus 569/H. Biochem. J., [S.l.], v.103, p.27c-30c, 1967.
LAGATOLLA C, et al. Molecular evolution of metallo-beta-lactamase- producing Pseudomonas aeruginosa in a nosocomial setting of high-level endemicity. J Clin Microbiol. [S.l.]; 44:2348–53, 2006.
LAGATOLLA C, et al. endemic carbapenem-resistant Pseudomonas aeruginosa with acquired metallo-b-lactamase determinants in european hospital. Emerg. Infect. Dis. 10: 535-538, [S.l.], 2004.
LANDERS T.F., et al. review of antibiotic use in food animals: perspective, policy, and potential. Public Health Rep. [S.l.], 127(1):4-22, 2012.
LEE J. K., et al. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant
[S.l.], 290–29510.1016/j.ijantimicag.2004.11.012, 2005
LEE K, et al. THE KOREAN NATIONWIDE SURVEILLANCE OF ANTIMICROBIAL RESISTANCE GROUP.. VIM and IMP-Type Metallo-b- lactamase producing Pseudomonas spp. And Acinetobacter spp. In Korean Hospitals. Emerg. Infect. Dis. [S.l.], 9: 868-871, 2003.
LEE MF, et al. Molecular characterisation of the metallo-beta-lactamase genes in imipenem-resistant Gram-negative bacteria from a university hospital in southern Taiwan. Int J Antimicrob Agents. [S.l.],;32:475–80, 2008.
LEE NY, et al. Clinical experiences of bacteremia caused by metallo-beta- lactamase-producing Gram-negative organisms. J Microbiol Immunol Infect. [S.l.]; 37:343–9, 2004.
LISTER PD, WOLTER DJ, HANSON ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. [S.l.];(22):582-610, 2009.
LIVERMORE D. M. Has the era of untreatable infections arrived? J Antimicrob Chemother. [S.l.]; 64 Suppl 1:29-36, 2008.
LIVERMORE, D. M. -lactamases in laboratory and clinical resistance. Clinicial Microbiology Review, [S.l.]; v. 8, n. 4, p. 557-84, 1995.
LIVERMORE, D. M.; WOODFORD, N. The -lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends in Microbiology, [S.l.]; vol.14, p.413-420, 2007.
LODISE TP, JR., et al. Predictors of 30- day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother. [S.l.]; 51(10):3510-5, 2007b.
LOUREIRO, M.M. et al. Pseudomonas aeruginosa: study of antibiotic resistance and molecular typing in hospital infection cases in a neonatal intensive care unit from Rio de Janeiro City, Brazil. Mem. Inst. Oswaldo Cruz., [S.l.]; v. 97, n. 3, p. 387-94. Apr. 2002.
ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol Mol Biol Rev. [S.l.]; 71(3):463–76, 2007.
LYCZAK J. B., CANNON C. L, PIER G.B. Establishment of Pseudomonas
aeruginosa infection: lessons from a versatile opportunist. Microbiol Infect 2.
[S.l.]; 1051–1060, 2000.
MAGALHÃES V, KELLY L.A, MAGALHÃES M. Metallo- -lactamase producing Pseudomonas aeruginosa strains isolated in hospitals in Recife, PE, Brazil. Braz J Microbiol. [S.l.]; 36:123–5, 2005.
MALTEZOU HC. Metallo- -lactamases in Gram-negative bacteria: introducing the era of pan-resistance? Int J Antimicrob Agents. [S.l.] ;33:405–411, 2009.
MARIENCHECK WI, et al. Pseudomonas aeruginosa elastase degrades surfactant proteins A and D. Am J Respir Cell Mol Biol[S.l.];28:528–537, 2003.
MARRA A.R., et al. Bloodstream infections with metallo-beta-lactamase- producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes. Antimicrob. Agents Chemother., 50 [S.l.]; pp. 388–390, 2006. MARTINEZ D. V. Betalactamasas tipo AmpC. Generalidades y métodos para detección fenotípica. Rev Soc Ven Microbiol. [S.l.];29:1315-2556, 2009.
MARTÍNEZ L, PASCUAL A, GARCÍA I, TRAN J, JACOBY GA. Interaction of plasmid and host quinolone resistance. J Antimicrob Chemother [S.l.]; 51:1037-9, 2003.
MARTÍNEZ-MARTÍNEZ L, PASCUAL A, JACOBY GA. Quinolone resistance from a transferable plasmid. Lancet [S.l.]; 351:797-9, 1998.
MATHAI, D.; JONES, R.N.; PFALLER, M.A.; SENTRY PARTICIPANT GROUP NORTH AMERICA. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance ProGram (North America). Diagn. Microbiol. Infect. Dis., [S.l.]; v. 40, n. 3, p. 129-36, Jul, 2001.
MELETIS, G.; BAGKERI, M. Pseudomonas aeruginosa : Multi-Drug-Resistance Development and Treatment Options. Infection Control, [S.l.]; p. 33–56, 2013.
MIGULA. N. Arbeiten aus dem Bakteriologischen Institut der Technischen Hochschule zu Karlsruhe, 1 [S.l.] pp. 235–238, 1894.
MILLER A. K., et al. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients.Antimicrob. Agents Chemother. [S.l.] 55 5761–5769 10.1128/AAC.05391-11, 2011
MOSKOWITZ S. M., et al. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosaisolated from colistin-treated cystic fibrosis patients. Antimicrob. Agents Chemother. [S.l.]; 56 1019–1030 10.1128/AAC.05829-11, 2012.
MUDAU M., et al. Outbreak of multi-drug resistant Pseudomonas aeruginosa bloodstream infection in the haematology unit of a South African academic hospital PLOS ONE, 8 [S.l.] pp. 1–7, 2013.
MURAKI Y., et al. Nationwide surveillance of antimicrobial consumption and resistance to Pseudomonas aeruginosa isolates at 203 Japanese hospitals in 2010. Infection, 41 pp. 415–423, 2013.
MURAMATSU H., et al. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa. Chemotherapy [S.l.]; 51, 70–7510.1159/000085612, 2005.
NAAS, T.; NORDMANN, P. OXA-type -lactamases. Current Pharmaceutical Design, [S.l.]v. 5, n. 11, p. 865-79, 1999.
NESME J., et al. Large-scale metagenomic-based study of antibiotic resistance in the environment. Curr Biol. [S.l.];24(10):1096-1100, 2014.
NEVES P.R., et al. Pseudomonas aeruginosa multirresistente: um problema endêmico no Brasil. J Bras Patol Med Lab [S.l.];47(4) 409-420, 2011.
NNIS - National nosocomial infections surveillance system. National nosocomial infections (NNIS) System Report, data summary from January 1992 through June 2004,. Am. J. Infect. Control. [S.l.];32(8):470–485, issued October 2004.
OLAITAN, A O., S M, and Rolain JM. “Mechanisms of Polymyxin Resistance: Acquired and Intrinsic Resistance in Bacteria.” Frontiers in Microbiology 5 [S.l.];643. PMC, 2014.
O'MALLEY YQ, et al. The Pseudomonas secretory product pyocyanin inhibits catalase activity in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol [S.l.];285:L1077–L1086, 2003a.
O'MALLEY YQ, et al. Subcellular localization of Pseudomonas pyocyanin cytotoxicity in human lung epithelial cells.Am J Physiol Lung Cell Mol Physiol [S.l.];284:L420–L430, 2003b.
OMIGIE, O., et al. Increasing resistance to quinolones: a four-year prospective study of urinary tract infection pathogens. International Journal of General Medicine, [S.l.]2, 171–175, 2009.
OTTER JA, YEZLI S, FRENCH GL. The role played by contaminated surfaces in the transmission of nosocomial pathogens. Infect Control Hosp
Epidemiol 32: [S.l.]; 687–699, 2011.
PADILLA E., et al. Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence. Antimicrob. Agents Chemother. [S.l.]54, 177–183. 10.1128/AAC.00715-09, 2010.
PAI H, et al. Epidemiology and clinical features of bloodstream infections cause by AmpC-type- -lactamases-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. [S.l.]; 48: 3720-8, 2004.
PALLERONI, N. J. Prokaryote taxonomy of the 20th century and the impact of studies on the genus Pseudomonas: a personal view. Microbiology [S.l.]; 149:1-7, 2003.
PAO SS, PAULSEN IT, SAIER MH., Jr Major facilitator superfamily. Microbiol Mol Biol Rev. [S.l.];62(1):1–34, 1998.
PARAMYTHIOTOU E, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis. [S.l.]; 38(5):670- 7, 2004.
PATEL JB, RASHEED JK, KITCHEL B. Carbapenemase in Enterobacteriaceae: activity, epidemiology, and laboratory detection. Clin Microbiol Newslett. [S.l.];31:55–62, 2009.
American Journal of Medicine, [S.l.] 119:S20-S28, 2006.
PEIX, A.; RAMÍREZ-BAHENA, M.H.; VELÁZQUEZ, E. Historical evolution and current status of the taxonomy of genus Pseudomonas. Infection, Genetics and Evolution, [S.l.]v.9, p. 1132-1147, 2009.
PELLEGRINO, F.L.P.C. et al. Ocurrence of a multidrug-resistant Pseudomonas aeruginosa clone in different hospitals in Rio de Janeiro, Brazil. J. Clin. Microb. [S.l.]; v. 40, n. 7, p. 2420-2424, Jul, 2002.
PEÑA C, et al. Nosocomial spread of Pseudomonas aeruginosa producing the metallo-beta-lactamase VIM-2 in a Spanish hospital: Clinical and epidemiological implications. Clin Microbiol Infect. [S.l.];13:1026–9, 2007.
PEREZ-PEREZ FJ, HANSON ND. Deteccion of plasmidmediated AmpC - lactamases genes in clinical isolates by using multiplex PCR. J Clin Microbiol. [S.l.]; 40: 2153-62, 2002.
PETROSINO JF, et al. Chromosomal system for studying AmpC-mediated - lactam resistance mutation in Escherichia coli. Antimicrob Agents Chemother. [S.l.]; 46: 1535-9, 2002.
PETTY N.K., et al. Global dissemination of a multidrug resistantEscherichia coliclone. Proc Natl Acad Sci U S A. [S.l.]; 111(15):5694-5699, 2014.
PFALLER, M.A.; et al. Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance proGram. Clin Infect Dis. [S.l.]; 15 v. 32, n. 2, p. S156-67. May. 2001.
PIER, G., RAMPHAL, R. Pseudomonas aeruginosa. In: MandellG, Bennett J, Dolin R. eds. Principles and pratice of infectious diseases. Philadelphia, PA: Elsevier Churchill Livinstone [S.l.]; p. 2587-2615, 2005.
PIRES EJVC, et al. Epidemiologic analysis of clinical isolates of Pseudomonas aeruginosa from an university hospital. Rev Bras Ter Intensiva [S.l.]; 21: 384- 390, 2009.
Pseudomonas aeruginosa. Principles and Practice of Infectious Diseases. 5 ed. Philadelphia, PA: Churchill Livingstone, [S.l.]; p. 2310-35, 2003.
POLLINI, S., et al. FIM-1, a new acquired metallo-beta-lactamase from a Pseudomonas aeruginosa clinical isolate from Italy. Antimicrob. Agents Chemother., [S.l.]; 57 pp. 410–416, 2013.
POOLE K. Efflux-mediated resistance to fluoroquinolones in Gram-negative bacteria. Antimicrob. Agents Chemother. [S.l.]; 44, 2233– 224110.1128/AAC.44.9.2233-2241.2000.
POOLE K. (). “Efflux pumps,” in Pseudomonas, Vol. 1. Genomics, life style and molecular architecture, ed. Ramos J. L., editor. (New York, NY: Kluwer Academic, Plenum Publishers), 635–674, 2004A.
POOLE K. (). Resistance to -lactam antibiotics. Cell. Mol. Life Sci. 61, 2200– 222310.1007/s00018-004-4060-9, 2004b.
POOLE K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. [S.l.]; 49, 479– 48710.1128/AAC.49.2.479-487. 2005.
POOLE K. Efflux pumps as antimicrobial resistance mechanisms. Ann. Med. [S.l.]; 39, 162–176, 2007.
POOLE K. Pseudomonas aeruginosa: resistance to the max. Front. Microbiol. [S.l.]; 2:65 10.3389/fmicb.2011.00065, 2011.
QUEENAN A. M., et al. Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole. Antimicrob. Agents Chemother. [S.l.]; 54, 4092– 409710.1128/AAC.00060-10, 2010.
RAETZ C.R. et al. Lipid A modification systems in Gram-negative bacteria. Annu. Rev. Biochem. [S.l.]; 76, 295–329. 10.1146/annurev.biochem.76.010307.145803, 2007.
RAMIREZ M. S., TOLMASKY M. E. Aminoglycoside modifying enzymes. Drug Resist. [S.l.]; 13, 151–17110.1016/j.drup.2010.08.003, 2010.
REINHARDT A., et al. Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. Antimicrob. Agents Chemother. [S.l.]; 51, 1341– 135010.1128/AAC.01278-06, 2007.
REJIBA S., et al. Contribution of parEmutation and efflux to ciprofloxacin resistance in Pseudomonas aeruginosa clinical isolates. J. Chemother. [S.l.]; 20, 749–752, 2008.
RENNIE RP, JONES RN, MUTNICK AH. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance ProGram (United States and Canada, 2000). Diagn Microbiol Infect Dis. [S.l.]; 45:287-93, 2003.
RIBERA A. et al. Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus -lactams. J. Antimicrob. Chemother. [S.l.]; first published online September 28, 2015 RODRIGUEZ-MARTINEZ J. M., POIREL L., NORDMANN P. Molecular